Centre d'épidémiologie sur les causes médicales de décès) Principales causes de décès en, 2008. ,
Advances in pain research and therapy, pp.59-75, 1979. ,
Pain and its treatment in outpatients with metastatic cancer cleeland CS, pp.592-596, 1994. ,
17-Properties of opiate-receptor binding in rat brain, 1973. ,
The effects of morphine-and nalorphine-like drugs in the non-dependent chronic spinal dog ,
27-morphine kinetics in cancer patients, NEJM J. Sawe,B. Dahlstrom, Paalzow L clinical pharmacology and therapeutics, vol.305, issue.305, pp.1417-1418629, 1981. ,
sur les traitements antalgiques médicamenteux des douleurs cancéreuses par excès de nociception chez l'adulte Bulletin du Cancer, Août 2003, Standards, Options et Recommandations 30-Oral morphine for cancer pain Wiffen PJ, Mc QUAY HJ Cochrane data batabase systematic review, pp.795-806, 2002. ,
The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects., British Journal of Clinical Pharmacology, vol.66, issue.6 ,
DOI : 10.1111/j.1600-0773.1990.tb00737.x
Analgesic efficacy of controlled-release oxycodone in postoperative pain Sunshine A ,
37-Characterization and validation of a pharmacokinetic model for controlled-release oxycodone ,
François Bore, Dominique Monnin Douleurs Évaluation -Diagnostic -Traitement, Intrathecal Drug Delivery, pp.140-146, 2008. ,
Current management of opioid-related side effects, Oncology, vol.15, pp.61-77, 2000. ,
Efficacy of senna versus lactulose in terminal cancer patients treated with opioids, Journal of Pain and Symptom Management, vol.15, issue.1 ,
DOI : 10.1016/S0885-3924(97)00276-5
Treatment of opioid-induced constipation with oral naloxone: A pilot study, Clinical Pharmacology and Therapeutics, vol.52, issue.1, pp.90-95, 1992. ,
DOI : 10.1038/clpt.1992.106
Oral naloxone reverses opioid-associated constipation, Pain, vol.84, issue.1, pp.105-109, 2000. ,
DOI : 10.1016/S0304-3959(99)00185-2
Aufhebung einer Morphin- induzierten Obstipation durch orales Naloxon, Der Anaesthesist, vol.46, issue.3, pp.191-194, 1997. ,
DOI : 10.1007/s001010050390
Methadone initiation and rotation in the outpatient setting for patients with cancer pain, Cancer, vol.11, issue.3, pp.520-528, 2010. ,
DOI : 10.1081/CNV-50482
Number 15 pp 1124-1132 The New England Journal of Medicine 86-Opioid Rotation for Toxicity Reduction In Terminal Cancer Patients Noémi D. de Stoutz, J Pain Symptom Manage, vol.33510, pp.378-384, 1995. ,
Indications, Outcomes, and Predictive Factors of Opioid Switching in an Acute Palliative Care Unit Sebastiano Mercadante, J Pain Symptom Manage, vol.37, pp.632-641, 2009. ,
Opioid hyperexcitability: the application of alternate opioid therapy Mac, Pain, pp.53-353, 1993. ,
Establishing ???Best Practices??? for Opioid Rotation: Conclusions of an Expert Panel, Journal of Pain and Symptom Management, vol.38, issue.3, pp.418-443, 2009. ,
DOI : 10.1016/j.jpainsymman.2009.06.002
Opioid Rotation: The Science and the Limitations of the Equianalgesic Dose Table, Journal of Pain and Symptom Management, vol.38, issue.3, pp.426-465, 2009. ,
DOI : 10.1016/j.jpainsymman.2009.06.001
101-. Difficult pain problems ,
73-83 Classification of opioid receptors, support care cancer International Union of Pharmacology. XII.. Pharmacol Rev, vol.948, issue.4, pp.567-592, 1996. ,
Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation, Journal of Pain and Symptom Management, vol.10, issue.4, pp.287-291, 1995. ,
DOI : 10.1016/0885-3924(95)00005-J
107-Synthetic substances with morphine-like effect Relationship between Analgesic Action and Addiction Liability, with a Discussion of the Chemical Structure of Addiction-Producing Substances, Bull. Org. mond. Sante, vol.14, pp.353-402, 1956. ,
History and recommendations for use in Analgesia, APS Bull, 2000. ,
Avis du 31 janvier 2007 et du 19 décembre 2007 concernant respectivement le chlorhydrate de méthadone en sirop et la méthadone en gélules ,
Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases, Pain, vol.25, issue.2, pp.171-86, 1986. ,
DOI : 10.1016/0304-3959(86)90091-6
Goodman and Gilman's The Pharmacologic Basis of Therapeutics, pp.521-55 ,
methadone and pethidine are noncompetitive N-methyl-d aspartate (NMDA) antagonists in the rat cortex and spinal, pp.553-562, 1998. ,
Methadone Use in Cancer Patients with Pain: A Review, Journal of Palliative Medicine, vol.5, issue.1, pp.127-165, 2002. ,
DOI : 10.1089/10966210252785097
Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer, Clinical Biochemistry, vol.33, issue.3, pp.197-202, 2000. ,
DOI : 10.1016/S0009-9120(00)00048-5
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE, Drug Metabolism and Disposition, vol.31, issue.7, pp.815-847, 2003. ,
DOI : 10.1124/dmd.31.7.815
Methadone Reincarnated: Novel Clinical Applications with Related Concerns, Pain Medicine, vol.3, issue.4, pp.339-387, 2002. ,
DOI : 10.1046/j.1526-4637.2002.02047.x
Support Care Cancer, pp.129-159, 2001. ,
The use of methadone for cancer pain, Hematology/Oncology Clinics of North America, vol.16, issue.3, pp.543-555, 2002. ,
DOI : 10.1016/S0889-8588(02)00017-5
Alpha1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome, Int. Journal of Clinical Pharmacology and Therapeutics, vol.38, issue.01, pp.35-40, 2000. ,
DOI : 10.5414/CPP38035
Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain, Clinical Pharmacology and Therapeutics, vol.41, issue.4 ,
DOI : 10.1038/clpt.1987.47
Methadone Reincarnated: Novel Clinical Applications with Related Concerns, Pain Medicine, vol.3, issue.4, pp.339-387, 2002. ,
DOI : 10.1046/j.1526-4637.2002.02047.x
High Interindividual Variability of Methadone Enantiomer Blood Levels to Dose Ratios, Archives of General Psychiatry, vol.55, issue.1 ,
DOI : 10.1001/archpsyc.55.1.89
CYP3A gene expression in human gut epithelium, CYP3A gene expression in human gut epithelium, pp.247-259, 1994. ,
DOI : 10.1097/00008571-199410000-00003
A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, vol.25, issue.3, pp.297-312, 1986. ,
DOI : 10.1016/0304-3959(86)90234-4
Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment, Clinical Pharmacology & Therapeutics, vol.18, issue.2, pp.180-190, 1975. ,
DOI : 10.1002/cpt1975182180
Oral and intravenous methadone use: some clinical and pharmacokinetic aspects, Drug and Alcohol Dependence, vol.55, issue.1-2, pp.137-143, 1999. ,
DOI : 10.1016/S0376-8716(98)00190-2
Methadone in the management of cancer pain: a review, Pain, vol.52, issue.2, pp.137-184, 1993. ,
DOI : 10.1016/0304-3959(93)90125-9
Methadone use in patients with chronic renal disease, Drug and Alcohol Dependence, vol.5, issue.3, p.197, 1980. ,
DOI : 10.1016/0376-8716(80)90180-5
Methadone, ciprofloxacin, and adverse drug reactions, The Lancet, vol.356, issue.9247, pp.2069-70, 2000. ,
DOI : 10.1016/S0140-6736(00)03409-7
Torsade de pointes associated with very-high-dose methadone ,
DOI : 10.1016/s1062-1458(02)01053-x
A report of three cases, Pain, vol.103, issue.3, pp.321-325, 2003. ,
188-Interaction of methadone and ethanol metabolism ,
qtdrugs.org/medical-pros/drug-lists/drug-lists.htm 190-Effect of corticosteroids on the expression of cytochromes ,
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262), Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol.18, issue.5, pp.435-478, 1998. ,
DOI : 10.1097/00042560-199808150-00004
The Effect of Oral Methadone on the QTc Interval in Advanced Cancer Patients: A Prospective Pilot Study Suresh Reddy, JOURNAL OF PALLIATIVE MEDICINE, vol.13, issue.1, pp.33-38, 2010. ,
Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home., Journal of Clinical Oncology, vol.16, issue.11, pp.3656-3661, 1998. ,
DOI : 10.1200/JCO.1998.16.11.3656
Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences, Annals of Oncology, vol.9, issue.1, pp.79-83, 1998. ,
DOI : 10.1023/A:1008263910494
Intravenous methadone in the management of chronic cancer pain, Cancer, vol.82, issue.7, pp.1919-1944, 2001. ,
DOI : 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3
Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine, Cancer, vol.35, issue.4, pp.852-859, 1996. ,
DOI : 10.1002/j.1552-4604.1995.tb04743.x
Dose ratio between morphine and methadone in patients with cancer pain, Cancer, vol.47, issue.6, pp.1167-73, 1998. ,
DOI : 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3/pdf
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain, Cancer, vol.72, issue.12, pp.2866-73, 2004. ,
DOI : 10.1016/S0304-3959(97)00018-3
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain, Pain, vol.96, issue.3, pp.325-333, 2002. ,
DOI : 10.1016/S0304-3959(01)00465-1
Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients, Journal of Clinical Oncology, vol.23, issue.22, pp.5229-5263, 2005. ,
DOI : 10.1200/JCO.2005.13.128
Opioid Rotation from Methadone: Fraught with Difficulties, Journal of Pain and Symptom Management, vol.29, issue.4 ,
DOI : 10.1016/j.jpainsymman.2005.02.006
Switching from Methadone to a Different Opioid: What Is the Equianalgesic Dose Ratio?, Journal of Palliative Medicine, vol.11, issue.8 ,
DOI : 10.1089/jpm.2007.0285
Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine, Journal of Clinical Oncology, vol.17, issue.10, pp.3307-3312, 1999. ,
DOI : 10.1200/JCO.1999.17.10.3307
The use of methadone in cancer pain poorly responsive to other opioids, Pain reviews, vol.5, issue.1, pp.51-58, 1998. ,
DOI : 10.1191/096813098673619329
Methadone titration in opioid-resistant cancer pain, European Journal of Cancer Care, vol.4, issue.1, pp.26-35, 1999. ,
DOI : 10.1016/S0305-7372(96)90075-4
Reduction in Constipation and Laxative Requirements Following Opioid Rotation to Methadone, A Report of Four Cases, Journal of Pain and Symptom Management, vol.18, issue.4, pp.303-309, 1999. ,
DOI : 10.1016/S0885-3924(99)00086-X
Reduction in Constipation and Laxative Requirements Following Opioid Rotation to Methadone, A Report of Four Cases, Journal of Pain and Symptom Management, vol.18, issue.4, pp.303-309, 1999. ,
DOI : 10.1016/S0885-3924(99)00086-X
Respiratory depression in a patient receiving oral methadone for cancer pain, Journal of Pain and Symptom Management, vol.10, issue.5 ,
DOI : 10.1016/0885-3924(95)00021-P
Methadone-Induced Respiratory Depression in a Patient with a History of Alcoholism, JOURNAL OF PALLIATIVE MEDICINE, vol.8, issue.5, pp.1062-1066, 2005. ,
QTc interval prolongation associated with intravenous methadone, Pain, vol.105, issue.3, pp.499-506, 2003. ,
DOI : 10.1016/S0304-3959(03)00205-7
Deaths of clients in methadone treatment in Texas: 1994???2002, Drug and Alcohol Dependence, vol.78, issue.1, pp.73-81, 2005. ,
DOI : 10.1016/j.drugalcdep.2004.09.006
Methadone for Pain: Limited Evidence, Tenuous Guidelines, The Journal of Pain, vol.10, issue.7, pp.774-775, 2009. ,
DOI : 10.1016/j.jpain.2009.04.010
Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations, Cancer Treatment Reviews, vol.22, pp.131-137, 1996. ,
DOI : 10.1016/S0305-7372(96)90075-4
Combination therapy with ibuprofen and methadone for chronic cancer pain Ferrer ,
Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study, Pain, vol.38, issue.2, pp.151-158, 1989. ,
DOI : 10.1016/0304-3959(89)90233-9
Double Blind Trial of Dextromoramide, Methadone and Pethidine in the Treatment of Severe Pain, Postgraduate Medical Journal, vol.40, issue.460, pp.103-108, 1964. ,
DOI : 10.1136/pgmj.40.460.103
A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, Journal of Pain and Symptom Management, vol.1, issue.4, pp.203-210, 1986. ,
DOI : 10.1016/S0885-3924(86)80042-2
Disparities Between Black and White Patients with Cancer Pain: The Effect of Perception of Control over Pain, Pain Medicine, vol.6, issue.3, pp.242-50, 2005. ,
DOI : 10.1111/j.1526-4637.2005.05038.x
266-Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system, 1996. ,
diagnostic, évaluation, traitement en médecine ambulatoire Recommandation pour la pratique clinique de la Société Française d'Étude et de Traitement de la Douleur Douleur analg, Management of neuropathic pain Troels S Jensen, Nanna Brix Finnerup In Pain 2010 an updated review, refresher course syllabus, pp.1-16, 2010. ,
Ghislain né le 15 Mars 1973 à Paris 270-Low dose of methadone has an analgesic effect in neuropathic pain: a double blind randomized controlled crossover trial, 2006. ,
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations, Pain, vol.113, issue.1, pp.9-19, 2005. ,
DOI : 10.1016/j.pain.2004.09.012
Constipation sous opioïde recommandantion par la Société Française d'Accompagnement et de Soins Palliatifs prise en charge médicale ,
???????????page 10 I-1-1, Description par temporalité................??????????????, p.11 ,
page 12 I-2-1page 12 I-2-2. Epidémiologie : l'enjeu de la douleur dans le cancerpage 12 I-2-2-1. Avant, ????????????????.??.page 13 I-2-2-2. Après 1986 ................?????????????????.?, p.13, 1986. ,
??page 17 II-1???????????page 18 II-2. Les différentes molécules d'opioïdes??????????.page 18 II-2-1, Transdermique...........................???....??????????, pp.22-24 ,
page 27 II-2-6-1. Forme buvable??????????????, Forme gélule????????????..................................?, pp.27-29 ,
???.page 30 II-4-1. La sédation, p.31 ,
page 32 II-4-4, pp.32-36 ,
page 35 III-1. Introduction : définitionpage 36 III-2. Pourquoi faire une rotation, pp.37-39 ,
.page 59 V-1. Sûreté d'utilisationpage 60 V-2, ., pp.63-66 ,
page 68 V-4-1. Naïf ou rotation.page 68 V-4-2. Les différents modèles d'instauration proposés : stop and go ou graduelle, systématique ou ab libitum, p.68 ,
page 83 VI-1. Manque de données des études, Du caractère peu formel et de la variabilité des pratiques des études en algologie et leurs limites, pp.84-86 ,
.page 87 VII-1. Introductionpage 88 VII-3page 94 VII-3-1. Description de la population, Les traitements antalgiques avant la rotation, pp.88-90 ,
.page 106 VII-3-3-2.page 107 VII-3-3-2-1. Retour à domicilepage 107 VII-3-3-2-2. Délai entre l'introduction de méthadone et la sortie de l'hôpitalpage 107 VII-3-4. Analyses des différentes variables pouvant influer sur les caractéristiques d'utilisation de la méthadone Recherche d'une significativité entre la méthadone à J7 et J28 et la durée d'exposition préalable aux opioïdes Recherche d'une significativité entre la méthadone à J7 et J28 et la survenue d'effets secondaires Analyses des différentes variables pouvant influencer sur la fréquence de survenue des effets secondaires, pp.106-109 ,